REPUBLIK INDONESIA
KEPUTUSAN
KEPALA BADAN PENGAWAS OBAT DAN MAKANAN
REPUBLIK INDONESIA
NOMOR 02002lSWKBPOM
TENTANG
TATA LAKSANA UJI KLlNlK
KEPALA BADAN PENGAWAS OBAT DAN MAKANAN
MEMUTUSKAN
BAB l
KETENTUAN UMUM
Bagian Pertama
Umum
lnstitusi yang melakukan Uji Klinik perlu mempunyai komisi llmiah dan Komisi
Etik sesuai ketentuan dalam pedoman CUKB.
Bagian Kedua
Komisi llmiah
BAB Ill
PENGAJUAN PELAKSANAAN UJI KLlNlK
Bagian Pertama
Uji Kiinik pra-Pemasaran
Bagian Ketiga
Uji Klinik Terbatas untuk Pendidikan
Pasal 10
Pasalll
Peneliti melaporkan semua Kajian Tidak Diinginkan serius dalam Uji Klinik
termasuk kematian kepada Sponsor atau Organisasi Riset Kontrak segera
setelah saat pertama diketahui, bila ada kejadian susulan, pelaporan dilakukan
secepatnya sampal rangkaian kejadian berakhir.
Sponsor melaporkan semua Kejadian Tidak Diinginkan serius dalam Uji Klinik
termasuk kematian kepada Badan dan Komisi Etik lnstitusi dalam waktu 15
(lima belas) hari terhitung sejak pertama diketahui, bila ada kejadian susulan,
pelaporan harus dilakukan secepatnya sampai rangkaian kejadian berakhir.
Sponsor harus melaporkan hasil Uji Klinik setelah pelaksanaan Uji Klinik selesai
kepada Kepala Badan.
BAB VI
PENGHENTIAN PELAKSANAAN UJI KLlNlK
Pasal I 6
BAB VII
INSPEKSI
BAB Vlll
PENGADAAN OBAT UNTUK UJI KLlNlK
Bagian Pertama
Obat Untuk Uji Klinik
1. Obat yang akan digunakan Uji Klinik harus dapat dijamin mernenuhi
persyaratan mutu dan telah melalui tahapan Uji pra-Klinik sesuai ketentuan.
2. Obat yang akan digunakan sebagal obat uji dan obat pembanding dalarn
pelaksanaan suatu Uji Klinik dapat berupa produk luar negeri atau produk
dalam negeri, baik yang sudah mernperoleh izin edar rnaupun yang belurn
memperoleh izin edar.
3. Penggunaan obat produk luar negeri dan produk dalam negeri yang belurn
memperoleh izin edar sebagaimana dimaksud pada ayat (2) harus
mendapatkan persetujuan dan Kepala Badan.
Bagian Kedua
lzin Pemasukan Obat Untuk Uji Klinik
1. Pengajuan izin pernasukan obat produk luar negri untuk keperluan Uji Klinik
dilakukan oleh Sponsor atau organisasi Riset Kontrak kepada kepala Badan.
2. Pengajuan izin pernasukan obat sebagaimana dimaksud pada ayat (1)
diajukan bersamaan dengan pengajuan pelaksanaan Uji Klinik, dan
dilengkapi dengan Persetujuan Komisi llmiah dan Komisi klinik, waktu
pelaksanaan, sumber obat, sertifikat CPOB produsen di luar negeri, jenis
serta jumlah obat yang diperlukan, sertifikat analisa, nornor batch obat yang
digunakan dalarn Uji klinik, dan pernyataan tertulis bahwa Sponsor serta
Peneliti bersedia untuk memenuhi standar CUKB.
3. Kepala Badan akan mernberikan persetujuan terhadap pengajuan
pemasukan obat produk luar negeri untuk Uji Klinik yang telah disertai
dokumen lengkap dalam waktu 10 (sepuluh) hari kerja dengan
menggunakan contoh Formulir UK-3 sebagaimana Lampiran Vl Keputusan
ini.
BAB IX
SANKSI
BAB XI
KETENTUANPENUTUP
ttd
Kepada Yth:
Kepala Badan Pengawas obat dan Makanan RI
Jln. Percetakan negara 23
JAKARTA
O
Pengajuan Persetujuan Pelaksanaan Uji Klinik Pra-pemasaran
Pemberitahuan Pelaksanaan Uji Klinik Pasca-Pemasaran 1
I. INFORMASI UMUM
Obat uji baru dimana tahapan Uji Klinik Pra-Pemasaran (fase I, 11,
ataupun Ill) masih berlangsung.
untuk indikasi baru cara pemberian baru, dosis baru dan lain-lain.
O Kategori IV
Obat yang sudah mendapat izin edar dan sedang dilakukan Uji Klinik
pasca-pemasaran.
.--..'
Ill. INFORMASI MENGENAI OBAT UJI
... .. .- . --.-. .' v u l ' .8 "0, .
Merupakan Obat :lmpor 0
- : lokal 0
? . Nama generic
2. Nama dagang
3. Narna kimia
6. kemasan
7. Cara pemberian
-
3
8. Tanggal kadaluarsa
9. Norno~batch
I 2. Nama dagang I
I 3. Nama kimia
4. kelas farmakologi
I
I
6. kemasan . .
7. Cara pembeitan
8. Tanggal kadaluarsa
9. Nomor batch
,
Kesimpulan Kajian Etik (tertampir)
-
Persetujuan Komisi llmiah (terlampir)
- No & tanggal Persetujuan:
- Nama & alamat istitusi:
--. BW Peneliti
Protokol l1de UjiKlinik
'
-- Pendelagsian scI&
Sebagiaafungsi
I
-- hmwhc?unl(ofi(!&h - P b m a b o ~ nKapEUn
-. Pletowupluna
h W W @
~~
.PmkPllOllqiXim
BFaVPMlhW
-rn&6MmIX,
Tin Pen~sshmQj
KW Enstanal
ParHJvrll
V'
XE- !CEJA
' J.A
RWUBLIKINUONIISIA
NOMOR OIMIYGWPOM
.
BADANPBNGAWAS OBAT DAN MAKANAN
m PcrusetlziUjl
- Rtlurpn pmlokd belch pmdu
(uo~~inlpod&
~drrji)
KRn* Nafoml
I 10 hari krija
ALURTATA CARA PERSIAPAN UJI KLMK PW-PEMASARAN
(Dalam ha1 komisi nmiah dan komisi Etika tcrpisah)
-- ~ro&~eneliti
Protokol t Ide Uji Klinik
- Pandelegasiians&tuh/
- Sebagian fuagai
.- Pcnnohrrn~nKoji
PemhmKajIEVk
llmiah
T CIIl
Pasetujuaa Komisi Uik
KEPUYUSANKEPAIA BADAH PEUGAWASOBAT DAN ~ KANAN
RePIWUKWESlA
NoMOROZO925KlKBWM
'ICNTAHGTATA LAKgANA W1 KLINIK .
ALUR TATACARA PERSIAPAN UJI KLINIK urn WNIK
TERSATAS UNNK PENDIDIKAN
(Dahm elm komisiIlmiah dan komisi Etika terpisoh)
Penanggw Jawab
P q r a m Pendid&
11 Badan POM
.nmAu-ff*ii-fifi* "jIIKUNK
ALUR TATA CARA PERSIAPAN UJI KLINIK US1 KLINIK
TERBATAS UNNK PENDLDLKAN
(Dalam ha1 Kajian Ilmiah dan Etik dilakukan di komisi Etik)
I Penarrggung Jawab
PmprnPendibh
/>
-) pefsetujuan Komisl - Etlk
DECREE OF THE HEAD OF
NATIONAL AGENCY OF DRUG AND FOOD CONTROL
REPUBLIC OF INDONESIA
No. 02002/SK/KBPOM
REGARDING
CLINICAL TRIAL PROCEDURE
Considering : a. That the system of drug and food control should be able
to detect, prevent and control efficiently and effectively
the drug and food, either before or after the marketing
approval to protect the community's safety and welfare;
b. That to protect the community's safety and welfare, the
efficacy, safety and quality of the marketed drug must be
adequately proven by valid clinical and quality data;
c. That there is a need to protect the right and safety of the
clinical trial subjects, and to review the scientific as well
as the ethical aspect in the clinical trial;
d. That there is a need to establish the Decree of the Head of
the National Agency of Drug and Food Control regarding
Clinical Trial Procedures.
DECIDES
CHAPTER I
GENERAL PROVISIONS
Article 1
Article 2
( I ) Clinical Trial in Indonesia should comply with the Indonesian Guideline
on Good Clinical Practice (Pedoman Cara Uji Kliizik yang Baik) and
should have scientifically benefit.
(2) Clinical Trial in Indonesia is classified as Pre-Marketing Clinical Trial, Post-
Marketing Clinical Trial and Clinical Trial for Educational Purposes.
(3) The implementation of Clinical Trial in Indonesia:
a. Those requiring regulatory's approval (Clinical Trial Approval Letter/
Persetujuan Pelaksanaan Uji Klirzik) for the pre-marketing trial.
b. Those requiring to notify to the regulatory (Notification) for the post-
marketing trial.
c. Those requiring to notify to the regulatory (Notification) for the trial
for educational purposes.
Article 3
The implementation of clinical trial should respect the rights and safety aspects
of the human subjects.
CHAPTER II
INSTITUTION
Part One
General
Article 4
The Institutions that conduct clinical trial need to have Scientific Committee
and Ethics Committee as stated in the Indonesian Guideline for Good Clinical
Practice (Pedoman Cara Uji Klinik yang Baik).
Part Two
Scientific Committee
Article 5
( 1 ) The Scientific Committeeas stated in Article 4 has the task to review the
scientific aspect independently and has the responsibility for its result
before proceeding to the Ethics Committee.
( 2 ) The Scientific Committee as stated in sub article ( 1 ) needs to have
collaboration with other related group in order to ensure the valid review
Part Three
Ethics Committee
Article 6
( 1 ) Ethics Cominittee as stated in Article 4 has the task to review the ethical
aspects independently.
( 2 ) In case there is no Ethics Committee in the Institution, ethical review
should be asked from the Ethics Committee from the nearest institution.
CHAPTER III
THE SUBMISSION OF CLINICAL TRIAL DOCUMENTS
Part One
Pre-Marketing Trial
Article 7
Part Two
Post-Marketing Trial
Article 8
Part Three
Trial for Educational Purposes
Article 9
CHAPTER IV
APPROVAL
Article 10
( 1 ) The Head of the Agency may ask for advice from the National Advisory
Board on Clinical Trial regarding the scientific or Ethics Committee's
approval for the Pre and Post-Marketing Trial.
( 2 ) The National Advisory Board on Clinical Trial stated in sub article ( 1 ) is
appointed by the Head of the Agency.
Article 11
( 1 ) The Head of the Agency issues the Clinical Trial Approval Letter
(Persetujuan Pelaksanaan Uji Klinik) for Pre-Marketing Trial within 10
working days after the submission of complete documents.
( 2 ) Clinical Trial Approval Letter (Persetujuan Pelaksanaan Uji Klinik) as
stated in sub article (1) is valid for 2 (two) years.
Article 12
(I) The Head of the Agency will give response to the Sponsor within 10
working days for Post-Marketing trials that needs special consideration.
( 2 ) Special consideration as stated in sub article ( 1 ) needed for trial that do not
contribute significant benefit to the community and the development of
scientific knowledge.
CHAPTER V
REPORTING
Article 13
Investigator should report all Serious Adverse Event including death to the
Sponsor or Contract Research Organization immediately and expedited
reporting conducted for the sequence events until the series of events last.
Article 14
Sponsor should report all Serious Adverse Event including death to the Head
of the Agency and Scientific/Ethics Committee within 15 (fifteen) calendar
days and expedited reporting conducted for the subsequent events until the
series of events last.
Article 15
The Sponsor reports all amendments and the result of Clinical Trial to the
Head of the Agency.
CHAPTER VI
TERMINATION OF CLINICAL TRIAL
Article 16
Article 17
The Head of the Agency can postpone, terminate or not issuing the approval
(Persetujuan Pelaksanaan Uji Klinik) for strong reasons in terms of scientific
or safety aspects after consulting the National Advisory Board on Clinical
Trial, although Scientific/Ethics Committee's approval has been obtained.
CHAPTER VII
GCP INSPECTION
Article 18
GCP Inspection is conducted on facilities, records, documents and other sources
in the trial sites, CRO or sponsors or other places related to the trial.
Article 19
Part One
Drug for Clinical Trial
Article 20
(1). Drug which is used in the trial must meet the quality requirements and
have pre-clinical study stages as required.
(2). Drug which is used as a study drug and comparator drug could be an
approved or an unapproved of local or imported drugs.
(3). Approval from the Head of Agency is needed for unapproved local and
imported drugs as stated in sub article (2).
Part Two
Import License for Trial Drugs
Article 21
(1) The application for the importation of trial drugs is applied by the Sponsor
or Contract Research Organization to the Head of the Agency to obtain the
approval.
(2) Application for the approval of trial drugs importation as stated in sub
article (1), is carried out simultaneously with the application for the
approval of the trial, completed with requirements as stated in the UK-I
form.
(3) The Head of the Agency will issue approval on the trial drug importation
within 10 working days after the submission of complete documents.
CHAPTER IX
SANCTION
Article 22
Sanction will be imposed for those who fails to follow the regulation as stated
in Article 2.
CHAPTER X
TRANSITIONAL PROVISION
Article 23
All provisions regarding clinical trial before the establishment of this decree
remain in place as long as it is not conflicting this decree.
CHAPTER XI
CLOSING PROVISION
Article 24
This decree shall take effect commencing from the date of its enactment.'
Ratified in Jakarta
ATTACHMENT I
DECREE OF T H EHEAD OF THE NATIONAL AGENCY OF DRUG
AND FOOD CONTROL
REPUBLIC OF INDONESIA
NO 02002/SK/KBPOM
REGARDING CLINICAL TRIAL PROCEDURES
To:
The Head of the National Agency of Drug and Food Control Republic of
Indonesia
Percetakan Negara 23
JAKARTA
I. GENERAL INFORMATION
5. Design :
7. Use of placebo :
8. Number of Subject :
9. Protocol, Investigator's Brochure, Informed Consent and a m e n d m e n t s
(if any)
Yes NO
Category I
New study medication that has never been studied in human before.
Category II
New study medication that phase I, II, or III trials is still being
conducted.
Category III
Study medication has been marketed and this trial is to be
conducted for new indication, new administered, and/or new
strength.
Category IV
Study medication has been marketed and its trial is being conducted
as Post-Marketing Trial.
II. INSTITUTIONS
Local Center :
Overseas Center :
Local
1. Generic name :
2. Trade name :
3. Chemical name :
4. Pharmacological Class :
6. Packaging :
7. Route of Adminislration:
8. Expiry date :
9. Batch number :
1 1. GMP certificate :
14. Imported by :
Local
1. Generic name :
2. Trade name :
3. Chemical name :
4. Pharmacological Class :
6. Packaging :
7. Route of Administration:
8. Expiry date :
9. Batch number :
14. Imported by :
(Stamp)
Signature
Name (Capital)
Date
(Stamp)
Signature
--
Date
FORM UK-2
ATTACHMENT V
Protocol's Title
Principal Investigator
Sponsor
Trial Site
Ethics Committee's Approval
with conditions :
1. The Scientific and ethical aspects are reviewed by the
Scientific/Ethic Committee.
2. Clinical Trial is conducted in accordance with the Good Clinical
Practice standards.
3. The Clinical Trial Approval letter is valid for 2 (two) years.
Head of The
National Agency for Drug and Food Control
FORM UK-3
ATTACHMENT VI
Jakarta,
No.
Enclosed : ..................
Re : Importation approval letter
for trial drugs
with conditions:
1. The above Trial drug (s) is derived from ................. and should
meet the quality requirements
2. The above trial drug (s) is only used for the Clinical Trial
(Clinical Trial Approval Letter No ........................) and not
for commercial purposes.
Head of The
National Agency for Drug and Food Control